Stryker Launches T2 Alpha Humerus Nailing System for Fracture Care
SYK launches the T2 Alpha Humerus Nailing System to enhance complex fracture care, boosting procedural efficiency and strengthening its trauma portfolio.
SYK Stock Gains as Q4 Earnings & Sales Beat on Strong Mako Adoption
SYK shares rise after fourth-quarter EPS and sales top estimates, fueled by double-digit organic growth and strong adoption of its Mako platform.
Stryker Corporation (SYK) Q4 2025 Earnings Call Transcript
Stryker Corporation (SYK) Q4 2025 Earnings Call Transcript
Compared to Estimates, Stryker (SYK) Q4 Earnings: A Look at Key Metrics
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
Stryker (SYK) came out with quarterly earnings of $4.47 per share, beating the Zacks Consensus Estimate of $4.4 per share. This compares to earnings of $4.01 per share a year ago.
SYK's Q4 Results Likely to Reflect Procedure Growth and Capital Demand
Stryker's fourth-quarter results are expected to highlight resilient procedure volumes and strong capital demand, supported by product momentum and broad-based strength.
Here's Why Stryker (SYK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gear Up for Stryker (SYK) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Stryker (SYK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker
Stryker offers above-average revenue growth, robust margin leverage, and a compelling valuation relative to med-tech peers despite sector-wide derating risks. Key growth drivers include Mako's continued share gains in major joints, expansion into extremities, and under-tapped potential in ambulatory surgical centers. Management prioritizes M&A for capital allocation, targeting complementary technologies in robotics, cardiology, and urology, while organic growth opportunities like Smart Care add upside.
Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside?
Intuitive Surgical's robotics-first model, recurring revenue base, and margin leverage differentiate it from Stryker in terms of upside potential today.
Why Stryker (SYK) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
